International Journal of Infectious Diseases (2010) 14, e158—e160
http://intl.elsevierhealth.com/journals/ijid
CASE REPORT
Brucellosis presenting as myelofibrosis: First case report Faris G. Bakri a,*, Nazzal M. Al-Bsoul b, Ahmad Y. Magableh b, Asem Shehabi c, Musleh Tarawneh d, Azmy M. Al-Hadidy e, Mohammed A. Abu-Fara a, Abdallah S. Awidi b a
Department of Medicine, Division of Infectious Diseases, Jordan University Hospital, PO Box 13046, Amman 11942, Jordan Department of Medicine, Division of Hematology and Oncology, Jordan University Hospital, Amman, Jordan c Department of Pathology—Microbiology, Jordan University Hospital, Amman, Jordan d Department of Pathology, Jordan University Hospital, Amman, Jordan e Department of Radiology, Jordan University Hospital, Amman, Jordan b
Received 8 January 2009; received in revised form 8 March 2009; accepted 15 March 2009 Corresponding Editor: Ziad Memish, Riyadh, Saudi Arabia
KEYWORDS Brucella; Pancytopenia; Myelofibrosis; Bone marrow
Summary We describe the case of a 29-year-old woman who presented with pancytopenia and myelofibrosis. Brucella melitensis was identified in her blood. The patient recovered completely with doxycycline and rifampin. A repeat bone marrow biopsy showed hypercellularity without myelofibrosis. Bone marrow findings in cases of pancytopenia due to brucellosis reveal normocellularity, hypercellularity, hemophagocytosis, or granuloma. To our knowledge this is the first report of brucellosis causing myelofibrosis. Brucellosis should be considered as a possible cause of myelofibrosis in endemic areas. # 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Introduction Brucellosis is a major zoonotic disease in several parts of the world including the Mediterranean region; it can affect any organ and can have various presentations.1,2 Pancytopenia is a known complication of brucellosis.2,3 Causes of pancytopenia in brucellosis include hypersplenism and/or bone marrow involvement with granuloma, hemophagocytosis, and rarely bone marrow hypoplasia.4,5 * Corresponding author. Tel.: +962 6 5353666x2474; fax: +962 6 5353388. E-mail address:
[email protected] (F.G. Bakri).
Here, we describe a case of brucellosis presenting with pancytopenia secondary to myelofibrosis. To our knowledge this is the first report of such a complication resulting from brucellosis.
Case report A 29-year-old woman, who used to drink raw milk, was healthy until July 2007 when she started to complain of fever, dry cough, arthralgia, loss of appetite, and generalized weakness. She presented to our hospital one month after the onset of her symptoms.
1201-9712/$36.00 # 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. doi:10.1016/j.ijid.2009.03.018
Brucellosis presenting as myelofibrosis
e159
Physical examination showed a sick, pale female, with blood pressure of 125/80 mmHg, temperature 38.5 8C, hepatosplenomegaly, purpuric rash on the lower extremities, and a tender and swollen left knee. Laboratory examination showed hemoglobin 7.5 g/dl, white blood cell count 1.3 109/l (neutrophils 37%, lymphocytes 55%), and platelets 20.8 109/l. A blood film showed dimorphic red blood cells and no blast cells. Lactate dehydrogenase was 1479 U/l (normal range 240—480 U/l). Both the prothrombin and partial thromboplastin times were normal. Coombs’ test was positive. Tests for hepatitis viruses B and C and HIV were all negative. A bone marrow biopsy (Figure 1) revealed myelofibrosis with proliferative phase. Initially, the patient received imipenem and fluconazole (days 1—2), which was then switched to ceftazidime and caspofungin (days 3—9). However, the patient remained febrile. Eight days after admission, a blood culture (BACTEC 9240) taken on the day of admission grew Brucella melitensis identified by culture, Gram staining, biochemical, and serotyping methods. Therefore, doxycycline 100 mg twice daily and rifampin 600 mg once daily were started, and her fever abated after 2 days. The serum agglutination titer for Brucella was 320. A transthoracic
Figure 2 Bone marrow biopsy after treatment showing (A) marked hypercellularity (H&E 20); (B) reticulin not increased in the marrow (reticulin, 20).
echocardiogram did not show any vegetation. Abdominal computed tomography (CT) showed hepatosplenomegaly with a liver size of 19 cm and spleen size of 22 cm. A chest CT showed right hilar lymphadenopathy. The patient finished 3 months of doxycycline and rifampin. Her hemoglobin rose to 13 g/l, white blood cell count to 5.8 109/l, and platelets to 101 109/l. A repeat bone marrow biopsy (Figure 2) in November 2007 showed hypercellular marrow with no evidence of fibrosis, malignancy, or granulomatous process. A repeat CT of the abdomen in May 2008 showed spleen and liver sizes of 16 cm. The patient continued to do well one year following her initial presentation. Her spleen became non-palpable and her repeat Brucella titer was 40.
Discussion
Figure 1 Bone marrow biopsy before treatment showing (A) fibrosis and hypocellular elements (H&E 20); (B) marked fibrosis (reticulin, 20).
Infection with Brucella is known to cause anemia, leukopenia, and to a lesser extent thrombocytopenia and pancytopenia. The frequency of pancytopenia ranges from 3% to 21%.6 Bone marrow findings in cases complicated by pancytopenia include normocellular or hypercellular marrow, granuloma, hemophagocytosis, and rarely hypoplasia.3—11 In
e160 these situations, neutropenia resolves following treatment of the infection. The cause of pancytopenia is poorly understood. However, due to the tendency to marrow hyperplasia, and splenomegaly and absence of hemolysis, hypersplenism was implicated as the cause of pancytopenia; it is also possible that Brucella organisms exert a direct inhibitory effect on marrow cells or they induce lymphocytes to release mediators that inhibit hematopoeisis.5,9 Considering that brucellosis can occur with leukemia, febrile neutropenia, and solid tumors,4,12,13 we could not determine initially whether the patient had myelofibrosis secondary to brucellosis, or the brucellosis occurred in a preexisting myelofibrosis. However, the remarkable clinical and bone marrow response after the treatment of the infection support the hypothesis that Brucella was the cause of the myelofibrosis. To our knowledge, this is the first report of myelofibrosis due to brucellosis. Myelofibrosis can be seen in a variety of conditions, including chronic granulocytic leukemia, acute myeloid leukemia, multiple myeloma, and chronic lymphocytic leukemia. Infectious causes include kala-azar,14 disseminated tuberculosis, histoplasmosis,15 and Epstein—Barr virus.16 Myelofibrosis can occur in cases of tuberculosis either due to hemophagocytosis,8 or through the effect of transforming growth factor (TGF)-b which is produced from the tuberculosis granuloma and promotes fibrosis in the bone marrow.17 The mechanism of development of myelofibrosis here is not completely understood. We did not find any evidence of hemophagocytosis in the bone marrow; therefore the development of myelofibrosis could be due to overproduction of cytokines such as TGF-b. In this regard Rafiei et al.18 reported that patients with brucellosis have an increased frequency of TGF-b1 high producer genotype, but on the other hand Akbulut et al.19 did not find significant differences in TGFb levels between controls and patients with brucellosis. Alternatively, myelofibrosis could occur secondary to an antibody-mediated autoimmune mechanism.20 In support of this possibility is the positive Coombs’ test, and the fact that brucellosis has been described with several autoimmune conditions such as glomerulonephritis,21 Henoch—Schonlein purpura,22 and thrombocytopenia.23 In conclusion, this is the first report describing brucellosis complicated by myelofibrosis. Physicians in endemic areas should be aware of this possible association and test for Brucella in cases of myelofibrosis. Conflict of interest: No conflict of interest to declare.
F.G. Bakri et al.
5.
6.
7.
8.
9.
10.
11.
12. 13. 14.
15.
16.
17.
18.
19.
References 20. 1. Shehabi A, Shakir K, el-Khateeb M, Qubain H, Fararjeh N, Shamat AR. Diagnosis and treatment of 106 cases of human brucellosis. J Infect 1990;20:5—10. 2. Colmenero JD, Reguera JM, Martos F, Sanchez-De-Mora D, Delgado M, Causse M, et al. Complications associated with Brucella melitensis infection: a study of 530 cases. Medicine (Baltimore) 1996;75:195—211. 3. Crosby E, Llosa L, Miro Quesada M, Carrillo C, Gotuzzo E. Hematologic changes in brucellosis. J Infect Dis 1984;150: 419—24. 4. Sari I, Altuntas F, Hacioglu S, Kocyigit I, Sevinc A, Sacar S, et al. A multicenter retrospective study defining the clinical and hema-
21.
22. 23.
tological manifestations of brucellosis and pancytopenia in a large series: hematological malignancies, the unusual cause of pancytopenia in patients with brucellosis. Am J Hematol 2008; 83:334—9. Yildirmak Y, Palanduz A, Telhan L, Arapoglu M, Kayaalp N. Bone marrow hypoplasia during Brucella infection. J Pediatr Hematol Oncol 2003;25:63—4. Akdeniz H, Irmak H, Seckinli T, Buzgan T, Demiroz AP. Hematological manifestations in brucellosis cases in Turkey. Acta Med Okayama 1998;52:63—5. Karakukcu M, Patiroglu T, Ozdemir MA, Gunes T, Gumus H, Karakukcu C. Pancytopenia, a rare hematologic manifestation of brucellosis in children. J Pediatr Hematol Oncol 2004;26:803—6. Martin-Moreno S, Soto-Guzman O, Bernaldo-de-Quiros J, Reverte-Cejudo D, Bascones-Casas C. Pancytopenia due to hemophagocytosis in patients with brucellosis: a report of four cases. J Infect Dis 1983;147:445—9. Al-Eissa YA, Assuhaimi SA, al-Fawaz IM, Higgy KE, al-Nasser MN, al-Mobaireek KF. Pancytopenia in children with brucellosis: clinical manifestations and bone marrow findings. Acta Haematol 1993;89:132—6. Garcia P, Yrivarren JL, Argumans C, Crosby E, Carrillo C, Gotuzzo E. Evaluation of the bone marrow in patients with brucellosis. Clinico-pathological correlation. Enferm Infecc Microbiol Clin 1990;8:19—24. Namiduru M, Gungor K, Dikensoy O, Baydar I, Ekinci E, Karaoglan I, et al. Epidemiological, clinical and laboratory features of brucellosis: a prospective evaluation of 120 adult patients. Int J Clin Pract 2003;57:20—4. Al-Anazi KA, Al-Jasser AM. Brucella bacteremia in patients with acute leukemia: a case series. J Med Case Rep 2007;1:144. Barutca S, Sivri B. Brucellosis and hepatocellular carcinoma: just a coincidence? Am J Gastroenterol 1998;93:854—5. Rocha Filho FD, Ferreira FV, Mendes Fde O, Ferreira FN, Karbage A, Alencar ML, et al. Bone marrow fibrosis (pseudo-myelofibrosis) in human kala-azar. Rev Soc Bras Med Trop 2000;33:363—6. Hoffman R, Ravandi-Kashani F. Idiopathic myelofibrosis. In: Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P, editors. Hematology: basic principles and practice. Philadelphia: Elsevier; 2005. p. 1255—76. Politano S, Maselli D, Zenali MJ, Nguyen A, Quintas-Cardama A. Bone marrow fibrosis and gelatinous atrophy associated with acute Epstein—Barr virus infection. Am J Hematol 2008;83: 606—7. Viallard JF, Parrens M, Boiron JM, Texier J, Mercie P, Pellegrin JL. Reversible myelofibrosis induced by tuberculosis. Clin Infect Dis 2002;34:1641—3. Rafiei A, Hajilooi M, Shakib RJ, Alavi SA. Transforming growth factor-beta1 polymorphisms in patients with brucellosis: an association between codon 10 and 25 polymorphisms and brucellosis. Clin Microbiol Infect 2007;13:97—100. Akbulut H, Celik I, Akbulut A. Cytokine levels in patients with brucellosis and their relations with the treatment. Indian J Med Microbiol 2007;25:387—90. Pullarkat V, Bass RD, Gong JZ, Feinstein DI, Brynes RK. Primary autoimmune myelofibrosis: definition of a distinct clinicopathologic syndrome. Am J Hematol 2003;72:8—12. Bakri FG, Wahbeh A, Mahafzah A, Tarawneh M. Brucella glomerulonephritis resulting in end-stage renal disease: a case report and a brief review of the literature. Int Urol Nephrol 2008;40: 529—33. Massasso D, Gibson K. Brucellosis mimicking Henoch—Schonlein purpura. Med J Aust 2007;186:602—3. Pappas G, Kitsanou M, Christou L, Tsianos E. Immune thrombocytopenia attributed to brucellosis and other mechanisms of Brucella-induced thrombocytopenia. Am J Hematol 2004;75: 139—41.
